Should germline gene editing of human embryos be permitted?
20 May 2026
The map · N = 6
Quoted sources show by default; hover any dot for its source.
Three positions on heritable human gene editing — the ethical frame each adopts, and the empirical-vs-value distinctions all three blur.
Germline editing to eliminate single-gene disorders prevents predictable suffering and should be permitted under careful regulatory frameworks. Huntington's, sickle cell anaemia, and cystic fibrosis cause documented lifetime suffering. CRISPR efficacy in animal models reached 95%+ correction in 2023. Public-health analysis suggests cumulative DALY reductions of significant magnitude.
Audit Unstated Risk-Symmetry Assumption Logic
Treats the harm of inaction (continued suffering) as symmetrically weighable against the harm of action (off-target effects in unknown generations). The asymmetric uncertainty — known suffering vs. uncertain but possibly catastrophic effects — is asserted rather than defended.
Audit the full article →Heritable modifications cross an ethical line that no clinical benefit framework justifies, because consequences propagate to future persons who cannot consent. Off-target effects detected in CRISPR-edited human embryos remain unresolved (Kosicki et al., 2018). Future-generation consent is structurally impossible. The principle has been preserved across major international bioethics frameworks despite technological progress.
Audit Argument from Ignorance Logic
Treats current uncertainty about consequences as decisive against permission, but the same logic — applied symmetrically — would have prevented vaccines, organ transplant, IVF, and many other interventions that turned out to be net beneficial.
Audit the full article →A narrow exception for documented severe single-gene disorders — Huntington's, Tay-Sachs — would prevent the worst suffering without opening the broader enhancement frontier. Single-gene severe disorders affect millions; their suffering is documented and predictable. A narrow regulatory frame distinguishes them from polygenic traits and enhancement applications where the science is far less developed.
Audit Unstated Institutional-Capacity Assumption Logic
Assumes regulatory institutions can reliably maintain narrow boundaries against pressure from technological capability and patient advocacy combined. International experience with assisted reproductive technology suggests this institutional capacity is not generic — it depends on conditions the argument does not specify.
Audit the full article →- Heritable Human Genome Editing · International Commission on the Clinical Use of Human Germline Genome Editing, 2020
- CRISPR-Cas9 in Human Embryos: 2023 Update · Nature Medicine, 2023
- Establishing Limits for Human Germline Genome Editing · WHO Expert Advisory Committee, 2021
- Public Attitudes Toward Germline Editing: An International Survey · Science, 2023